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Abstract
Objective: Augmented renal clearance (ARC) is associated with sub-therapeutic antibiotic, anti-
epileptic, and anticoagulant serum concentrations leading to adverse patient outcomes. We
aimed to describe the prevalence and associated risk factors for ARC development in a large,
single-centre cohort in the United Kingdom.
Methods: We conducted a retrospective observational study of critically unwell patients admit-
ted to intensive care between 2014 and 2016. Urinary creatinine clearance was used to deter-
mine the ARC prevalence during the first 7 days of admission. Repeated measures logistic
regression was used to determine risk factors for ARC development.
Results: The ARC prevalence was 47.0% (95% confidence interval [95%CI]: 44.3%–49.7%). Age,
sex, Acute Physiology and Chronic Health Evaluation (APACHE) II score, and sepsis diagnosis
were significantly associated with ARC. ARC was more prevalent in younger vs. older (odds ratio
[OR] 0.95 [95%CI: 0.94–0.96]), male vs. female (OR 0.32 [95%CI: 0.26–0.40]) patients with lower
vs. higher APACHE II scores (OR 0.94 [95%CI: 0.92–0.96]).
Conclusions: This patient group probably remains unknown to many clinicians because mea-
suring urinary creatinine clearance is not usually indicated in this group. Clinicians should be
aware of the ARC risk in this group and consider measurement of urinary creatinine clearance.
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Background
During critical illness a number of patho-
physiological factors alter the pharmacoki-
netic and pharmacodynamic (PK/PD)
handling of drugs.1 Alterations in hepatic
enzyme activity, plasma protein concentra-
tion, and the volume of distribution (Vd) of
drugs are common.1 Similarly, organ failure
and in particular renal failure can result in
reduced elimination of drugs, potentially
leading to accumulation and toxicity.2,3
Routine monitoring of renal function
has traditionally been aimed at detecting
renal impairment and drugs relying on
renal elimination should undergo dose
adjustment to prevent toxicity.2–4
However, the phenomenon of a state of
supra-physiological renal function known
as augmented renal clearance (ARC) is
increasingly recognised.2,4 ARC is defined
as enhanced renal clearance and elimination
of circulating solutes and is thought to be
driven by a physiological increase in glo-
merular filtration rate (GFR).5
The presence of ARC is based upon
measured urinary creatinine clearance
(CrCl). CrCl values ranging from >120
mL/minute/1.73 m2 to >150 mL/minute/
1.73 m2 have been used to define ARC in
the literature.2 Despite variations in the
exact CrCl value to be used, there is evi-
dence to suggest that CrCl >130 mL/
minute/1.73 m2 can lead to subtherapeutic
plasma concentrations of drugs such as
antibiotics, in particular beta-lactams, gly-
copeptides, and aminoglycosides, as well as
anticoagulants and antiepileptic
medications.6,7 This observation has led to
a general consensus that CrCl >130 mL/
minute/1.73 m2 is an acceptable and clini-
cally important cut off value for the defini-
tion of ARC.2,5,8
A recent systematic review estimated the
prevalence of ARC at 20% to 65% of
admissions to the intensive care unit
(ICU).2 Despite this high prevalence, detec-
tion of ARC in the critically unwell is chal-
lenging because it often occurs with a
normal serum creatinine concentration
and with little indication in biochemical
markers of its presence.9 Furthermore,
surrogate markers for renal function and
estimation of GFR, such as the
Cockcroft–Gault (CG), Modified CG,
4-variable Modification of Diet in Renal
Disease (MDRD-4), 6-variable
Modification of Diet in Renal Disease
(MDRD-6), and Chronic Kidney Disease
Epidemiology Collaboration (CKD-EPI)
scores, tend to underestimate CrCl values
and rely upon serum creatinine being in a
steady state, which is not often the case in
critically unwell patients.10,11 Poor correla-
tion with estimated GFR coupled with few
ICUs routinely measuring CrCl has led to
the introduction of a number of scoring sys-
tems aimed at improving the detection of
ARC.2,12 Such scoring systems may help
to identify patients in which formal CrCl
measurement may be beneficial to assess
for ARC and guide drug therapy and dose
adjustment for renally cleared medications.
In 2014 our institution introduced con-
tinuous antibiotic infusions with daily dose
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adjustment guided by routine daily mea-
surement of CrCl, thus providing a rich
data source of renal function across a
broad cohort of critical care admissions.
To the best of our knowledge there are
few data in the literature regarding the
prevalence of ARC and its associated risk
factors in a British critical care population.
In the present study, we aimed to examine
the prevalence of ARC, determine risk fac-
tors associated with ARC, investigate the
development of ARC during the first
7 days of critical illness, and assess
whether the Augmented Renal Clearance
in Trauma Intensive Care (ARCTIC)
score can be used as a screening tool for
ARC in a cohort of mixed surgical and




We conducted a retrospective observational
cohort study of patients admitted to the
ICU of the Royal Blackburn Teaching
Hospital between January 2014 and
December 2016. The Royal Blackburn
Teaching Hospital is a 24-bed tertiary refer-
ral centre for patients with hepatobiliary ill-
nesses which has an increased proportion of
young patients with pancreatitis compared
with similar sized institutions. It is not a
regional trauma centre and therefore
admits comparatively few trauma patients.
The study was granted Health Research
Authority approval on 2 February 2017
(IRAS project ID 220861) following pro-
portionate ethical review as the study ana-
lysed clinical data routinely collected by the
clinical team which were then anonymised.
Therefore, the requirement for individual
patient consent was waived for this study.
Patient selection
Patients were eligible for inclusion if they
were an inpatient in the ICU, were over
18 years of age, and had a CrCl value mea-
sured within 24 hours of admission.
Patients were excluded from the analysis if
they suffered acute kidney injury (AKI),
defined as serum creatinine> 110 mmol/L
on or during admission; had documented
Kidney Disease: Improving Global
Outcomes (KDIGO) stage 5 chronic
kidney disease (CKD) or end-stage renal
failure (ESRF); or underwent renal replace-
ment therapy (RRT) during ICU
admission.13
Data collection and definition of ARC
Data were extracted from electronic medi-
cal records and anonymised prior to analy-
sis. Demographic data including age, sex,
height, weight, diagnosis of diabetes melli-
tus, and presence of KDIGO stage 5 CKD
or ESRF were recorded. Acute Physiology
and Chronic Health Evaluation (APACHE)
II scores, length of ICU stay, level of car-
diovascular support, and admission diagno-
sis were extracted from the ICU
Wardwatcher database. This database cap-
tures data on all critical care admissions for
transmission to the Intensive Care National
Audit and Research Centre (ICNARC).
Admission diagnosis was coded as 1)
sepsis, 2) post-operative patients without
sepsis, 3) pancreatitis 4) trauma, or 5)
other. Daily serum creatinine levels, daily
blood glucose levels, and daily 6-hourly
CrCl levels were extracted from electronic
laboratory results, and 6-hourly urine sam-
ples were collected from an indwelling uri-
nary catheter daily between 2200 and 0400.
Urinary creatinine measurement was under-
taken on the entire 6-hour diuresis and uti-
lised automated analysers employing the
enzymatic Ortho Vitros method (Ortho
Clinical Diagnostics, Raritan, NJ, USA).
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Creatinine clearance was calculated using
the standard formula: CrCl (mL/minute)-
¼ (6 hourly urinary volume (mL)
UrinaryCr (mmol/L)/(PlasmaCr (mmol/L)
 360 minutes) and was corrected for body
surface area (BSA) using the formula:
Corrected CrCl¼CrCl (1.73 m2/BSA)2.
BSA was estimated using the Du Bois for-
mula: BSA¼ 0.007184weight
(kg)0.425height (cm)0.725 14. The presence
of ARC was defined as CrCl> 130 mL/
minute/1.73 m2.
Outcomes
Our primary outcome of interest was to
define the overall prevalence and prevalence
for the development of ARC on each day of
the first 7 days of ICU admission.
Secondary outcomes were to identify inde-
pendent risk factors associated with the
development of ARC and to assess the pre-
dictive ability of the ARCTIC score to pre-
dict ARC in our patient cohort.
Statistical analysis
All data were de-identified and anonymised
prior to analysis. Baseline and measured
study characteristics are presented as
medians and interquartile ranges (IQR)
for continuous variables and as counts
(%) for categorical variables.
The prevalence of ARC with 95% confi-
dence intervals was calculated as the
number of patients with ARC out of the
number of patients with a recorded CrCl
value. Overall prevalence was defined as
any patients developing ARC during
admission, and the daily prevalence over
the first 7 days of admission was calculated.
Occurrence of ARC was modelled as a
binary response. Repeated measures on
individuals were available, and our area of
interest was the population rather than
individual prediction. Accordingly, we
used repeated measures logistic regression
with possible risk factors as explanatory
variables, and fitted a population-averaged
model. Candidate explanatory variables
used in univariate analysis included age,
height, weight, BSA, ICU length of stay,
level of cardiovascular support, APACHE
II score, sex, admission serum glucose
levels, APACHE II mortality, and admis-
sion diagnosis. Explanatory variables for
the model were selected using backward
selection with a cut-off p-value of 0.05 sig-
nifying significance.
Odds ratios were calculated and are
reported for significant explanatory varia-
bles. We assessed the ARCTIC scoring
system in predicting ARC.14 We limited
the analysis to day 1 of admission because
the ARC status of our cohort was not con-
stant throughout admission. All statistical
analyses were carried out using STATA 16
software (StataCorp LP; College Station,
TX, US).
Reporting of our study conforms with
broad EQUATOR guidelines, and specifi-
cally with the STROBE checklist for retro-
spective studies.15
Results
During the 2-year study period, complete
data were available for 1751 individual
adult patients. Following exclusion of
patients who were admitted with or devel-
oped AKI during their ICU stay, required
RRT, or had documented KDIGO stage 5
CKD or ESRF, data for 1328 individual
patients were available for analysis
(Figure 1).
Patient characteristics
The median age of our patient cohort was
64 years (IQR 50–73) with more male (714
(53.7%)) than female (614 (46.2%))
patients. Our study cohort had a median
weight of 74 kg (62–87.5 kg) and a
median height of 1.68 m (1.60–1.75 m).
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The median length of ICU stay was 3.3
days (1.9–6.8 days).
The majority of the patients included
(1037, 78.1%) had no previous diagnosis
of diabetes mellitus. The main characteris-
tics of our entire patient cohort are pre-
sented in Table 1.
Prevalence of ARC
The adjusted prevalence of ARC in our
cohort was 47.0% (95% CI¼ 44.3%–
49.7%). Within this cohort, 624 or 47%
(95% CI¼ 44.3%–49.7%) had ARC at
some point during their ICU stay, 272 or
20.5% (95% CI¼ 18.4%–22.7%) had
ARC throughout their stay, which never
resolved; a further 185 or 13.9% (95%
CI¼ 12.2%–15.9%) had ARC that resolved
at some point during the ICU stay, and 167
or 12.6% (95% CI 10.9%–14.5%) had
intermittent ARC that was unresolved
during the ICU stay. For patients remain-
ing in the ICU for 7 days or longer, the
prevalence of ARC ranged from 22.1% to
24.9% over the first 7 days (Table 2). The
median time to onset of ARC was 1 day
with over 64% of patients that developed
ARC doing so within 24 hours.
ARC was more common among men
with a prevalence of 36.9% compared
with 35.5% among women (p<0.001).
Patients that developed ARC tended to be
significantly (p<0.001) younger (median
age 56 years) compared with those that
did not develop ARC (median age 68
years). We could not identify an age thresh-
old below which ARC was more likely;
however, the likelihood of developing
ARC decreased with increasing age
(Figure 2).
Patients with ARC had a median length
of ICU stay of 3.8 days (IQR 1.9–7.7 days)
compared with 3.1 days (IQR 1.9–6.1 days)
for those without ARC. Patients with ARC
had a larger median BSA of 100 m2 (IQR
82–116 m2) compared with 82 m2 (IQR 69–
97 m2) for patients without ARC. Median
APACHE II score was 14 (11–18). Patients
without ARC were more unwell with
median APACHE II score of 15 (12–19)
compared with 13 (10–16) for those with
ARC. Comparisons between patients with
and without ARC are shown in Table 1.
Risk factors and prediction of ARC
With logistic regression prior to backward
selection of the promising explanatory var-
iables, age (OR 0.95 [95% CI¼ 0.94–0.96,
p<0.001]) and sex (OR 0.52 [95%
CI¼ 0.40–0.69, p<0.001]), high glucose
(defined as glucose >12–41 mmol/L) in
the first 24 hours (OR 0.98 [95%
Paents with complete 
data available 
n = 1751
Paents aer removal 
of KDIGO stage 5 CKD or 
ESRF
n = 1724
Records aer removal 
of paents with CKD 




27 paents excluded 
from analysis as KDIGO 
stage 5 CKD/ESRF or 
RRT
396 paents excluded 
due to AKI, or SCr >
110mmol/L
Figure 1. Flow diagram of patients included in
logistic regression analysis.
KDIGO, Kidney Disease: Improving Global
Outcomes; CKD, chronic kidney disease; ESRF,
end-stage renal failure; RRT, renal replacement
therapy; AKI, acute kidney injury; SCr, serum
creatinine.
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CI¼ 0.95–1.00, p<0.027]), and date of
onset of ARC within 24 hours where signif-
icantly associated with development of
ARC (Table 3). There was weak evidence
for APACHE II score (OR 0.97 [95%
CI¼ 0.94–1.01, p¼ 0.11]) and correlation
with development of ARC. No other
explanatory variables (height, weight,
BSA, length of stay, level of cardiovascular
support, low glucose levels, admission
Table 1. Demographic, admission, and illness severity data in patients with and without ARC (at any time).
Whole cohort
(n¼ 1328) ARC (n¼ 624)
Non-ARC
(n¼ 704) p-value
Age (years), median (IQR) 64 (50–73) 56 (43–68) 68 (58–78) <0.001
Sex, male, n (%) 714 (53.8%) 406 (65.0%) 308 (43.8%) <0.001
Sex, female, n (%) 614 (46.2%) 218 (35.0%) 396 (56.2%) <0.001
Height, median (IQR) 168 cm (160–175 cm) 171 cm (164–178 cm) 165 cm (157–173 cm) <0.001
Weight, median (IQR) 74 kg (62–87.5 kg) 81 kg (68–93 kg) 68 kg (59–80 kg) <0.001
BSA (m2), median (IQR) 89.2 m2 (73–108 m2) 99.6 (81.8–116.2) 81.7 (68.6–97.1) <0.001
Diabetes mellitus n (%) 291 (21.9%) 73 (25%) 218 (74%) 0.006
APACHE II score, median (IQR) 14 (11–18) 13 (10–16) 15 (12–19) <0.001
Length of stay, n, (IQR) 3.30 days (1.88–6.79 days) 3.80 (1.91–7.67) 3.06 (1.85–6.05) <0.001
Admission diagnosis, n (%)
Sepsis 349 (26.2%) 145 (23.2%) 204 (29.0%) 0.017
Post-operative without sepsis 419 (31.5%) 183 (29.3%) 236 (33.5%) 0.10
Pancreatitis 29 (2.1%) 22 (3.5%) 7 (1.0%) 0.002
Trauma 29 (2.1%) 15 (2.4%) 14 (2.0%) 0.62
Other 502 (37.8%) 259 (41.5%) 243 (34.5%) 0.009
KDIGO renal classification between patients with and without ARC
eGFR >90 mL/minute/1.73 m2 623 (99.8%) 678 (96.3%) 1
eGFR 60–90 mL/minute/1.73 m2 0 (0.0%) 1 (0.14%) 0.35
eGFR 45–59 mL/minute/1.73 m2 0 (0.0%) 2 (0.28%) 0.19
eGFR 30–44 mL/minute/1.73 m2 1 (0.16%) 20 (2.84%) <0.001
eGFR 15–29 mL/minute/1.73 m2 0 (0.0%) 3 (0.43%) 0.10
ARC, augmented renal clearance; IQR, interquartile range; BSA, body surface area; APACHE II, Acute Physiology and
Chronic Health Evaluation II; KDIGO, Kidney Disease: Improving Global Outcomes; eGFR, estimated glomerular
filtration rate.
Table 2. Daily prevalence of ARC over the first 7
and subsequent days (n¼ 1328).
Day ARC n (%) Non-ARC n (%)
1 281 (45.8%) 333 (54.2%)
2 98 (45.6%) 117 (54.4%)
3 52 (40.0%) 78 (60.0%)
4 46 (63.0%) 27 (37.0%)
5 20 (40.8%) 29 (59.2%)
6 17 (50.0%) 17 (50.0%)
7 14 (50.0%) 14 (50.0%)
8þ 96 (51.9%) 89 (48.1%)
ARC, augmented renal clearance. Figure 2. Scatter plot showing the prevalence of
ARC versus age in patients that developed ARC at
any point during admission.
ARC, augmented renal clearance.
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diagnosis) were significantly associated with
the development of ARC in unadjusted
analysis (Table 3).
Following backward logistic regression
for multiple explanatory variables, the sig-
nificant associations were preserved. In par-
ticular, ARC was found to be significantly
associated with younger vs. older age (OR
0.95 (95% CI¼ 0.94–0.96, p<0.001)), male
vs. female sex (OR 0.52 (95% CI¼ 0.39–
0.69, p<0.001)), and diagnosis of sepsis
(OR 0.763 (95% CI¼ 0.592–0.984
p¼0.037)). APACHE II score, while not
significant in unadjusted analysis, was sig-
nificant following adjusted analysis, with a
lower vs. higher APACHE II score being
associated with ARC (OR 0.95 [95%
CI¼ 0.93–0.97, p<0.001]).
In assessing the ARCTIC scoring system
we used ARC status of CrCl >130 mL/
minute/1.73 m2 and found that the
ARCTIC score had a sensitivity of 0.72
(95% CI¼ 0.67–0.76) and specificity of
0.63 (95% CI¼ 0.60–0.66) for predicting
ARC. We found that of 565 patients
having a positive ARCTIC score (6 or
more), 289 had ARC, giving a positive pre-
dictive value of 51.1% (95% CI¼ 47%–
55%). Of the 585 patients with negative
ARCTIC score, 473 did not have ARC,
giving a negative predictive value of
80.9% (95% CI¼ 77.5%–83.8%).
Table 3. Population-averaged risk factors for ARC in model before backward selection.*
Variable Odds ratio (95% CI) p-value
Unadjusted population-averaged risk factors for ARC
Age 0.949 (0.942–0.956) <0.001
Sex 0.523 (0.397–0.689) <0.001
Height 1.030 (0.986–1.075) 0.188
Weight 1.030 (0.943–1.125) 0.515
BSA 0.997 (0.927–1.072) 0.937
Length of stay 1.018 (0.977–1.060) 0.393
APACHE II score 0.972 (0.939–1.006) 0.105
APACHE II mortality prediction 0.995 (0.983–1.006) 0.339
Advanced Cardiovascular support 0.957 (0.871–1.051) 0.359
Low glucose within first 24 hours 1.039 (0.983–1.099) 0.179
High glucose within first 24 hours 0.972 (0.948–0.997) 0.027
Date of onset of ARC 0.999 (0.999–0.999) 0.018
Adjusted population-averaged risk factors for ARC after backward selection
Age 0.951 (0.944–0.958) <0.001
Sex 0.518 (0.393–0.685) <0.001
Height (cm) 1.043 (1.030–1.057) <0.001
BSA 0.981 (0.964–0.998) 0.001
APACHE II score 0.953 (0.932–0.974) <0.001
Low glucose within first 24 hours 1.057 (1.000–1.169) 0.048
High glucose within first 24 hours 0.977 (0.953–1.001) 0.062
Date of onset of ARC 0.999 (0.999–0.999) 0.011
Diagnosis of sepsis 0.764 (0.592–0.984) 0.03
*Except for renal diagnosis code, with which the model would not converge as there were no values apart from zero with
arc¼1, and the term was non-significant in the model.
ARC, augmented renal clearance; CI, confidence interval; BSA, body surface area; APACHE II, Acute Physiology and
Chronic Health Evaluation II.
Johnston et al. 7
Discussion
In this retrospective observational study, we
have shown that ARC is a frequent occur-
rence in a large cohort of 1328 patients in a
mixed medical and surgical ICU. The over-
all prevalence of 47.0% highlights that a
significant number of patients develop
ARC during admission to ICU. Our
observed prevalence is in keeping with
that of similar observational studies esti-
mating that 20% to 65% of critically ill
patients will develop ARC at some point
during ICU admission.5,4,16–19 In patients
with ARC in our analysis, 20.5% remained
in ARC status throughout their admission.
Similar findings have been reported by De
Waele et al.,20 who showed that ARC was
permanently present in 23% of patients but
transient in 35% of mixed medical and sur-
gical patients admitted to ICU. Grootaert
et al. found that 40% of patients that devel-
oped ARC had CrCl> 120 mL/minute/1.73
m2 for at least 5 days while Udy et al. and
Fuster–Lluch et al.4,21,22 reported that the
highest prevalence of ARC was on day 5
after admission to ICU.
We found that age, sex, APACHE II
score, and diagnosis of sepsis were signifi-
cantly associated with ARC. ARC was pre-
sent in younger (56 vs. 68 years), male
patients with lower APACHE II scores
(13 vs. 15). Younger age has been consis-
tently linked with ARC in a number of
studies, and a recent systematic review
reported an average difference of 10 years
between patients with and without
ARC.2,8,9,23 ARC is rarely found in patients
over 50 years, and Ruiz et al.2,24 reported
using <58 years as a screening cut off for
ARC. While our findings did not establish
an age threshold above which ARC was
absent, there was a clear trend towards
fewer patients with ARC as age increased.
GFR decreases with age, with studies esti-
mating a decline of 8 mL/minute/1.73 m2
during each decade after the age of 40
years.25 A number of reasons for this
decline have been postulated, including
reduction in glomerular capillary plasma
flow rate through reduction in afferent arte-
riolar resistance and increased glomerular
hydraulic pressure resulting in reduced
GFR.25 Coupled with structural changes
associated with aging such as reduced
renal mass and tubulointerstitial fibrosis,
it is likely that a reduction in GFR accounts
for the trend in reduced ARC with increas-
ing age observed in our cohort.25
The association between ARC and youn-
ger age likely explains the relationship
between ARC and illness severity scores
such as APACHE II and the Simplified
Acute Physiology Score (SAPS-II) as well
as the shorter ICU length of stay in the
patients with ARC in our cohort. In multi-
ple studies, lower APACHE II or SAPS-II
score has been shown to be a risk factor for
the development of ARC.2,5,6,16,26
However, this relationship has not been
observed in studies that used the
Sequential Organ Failure Assessment
(SOFA) score, which does not include age
as a variable.23 Kawano et al., in a study of
111 patients, revealed that APACHE II
score but not SOFA score was associated
with ARC when both scores were measured
in the same cohort of patients, and reported
that this difference following multivariate
analysis could likely be explained by the
influence of age on APACHE II and
SAPS-II.23 In our study, it is plausible
that the inclusion of age in the APACHE
II score is responsible for the observed asso-
ciation with ARC.
In common with other studies, we found
that ARC was more prevalent in male
patients.17,26 Baptista et al.18 reported that
ARC was more common in male trauma
patients with lower SOFA scores and
requiring vasopressor support. While our
cohort displayed more cases of ARC
among male patients, we did not find a sig-
nificant association between ARC and
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vasopressor use or the requirement for
advanced cardiovascular support. Trauma
has been described as a risk factor for
ARC in multiple studies, although the
mechanism by which trauma leads to
ARC remains unclear.6,23,24,27 Our ICU
admits relatively few trauma patients, yet
the association between ARC and younger
male patients remained, suggesting that the
association between trauma and ARC may
actually reflect the demographic of patients
that are more likely to present following
trauma rather than a true physiological
influence.4,28 Despite this, trauma has
been shown to be a significant risk factor
in a number of multivariate analyses, and
Barletta et al.16,17,24 recently developed a
scoring system for use in trauma patients
to predict ARC. The ARCTIC scoring
system has previously been reported to pre-
dict ARC with a sensitivity of 0.84 and spe-
cificity of 0.68 in 133 trauma patients by
combining variables that we also found to
be significantly associated with ARC, such
as age, male sex, and low serum creatinine
levels.17 In our cohort we found that the
ARCTIC score had a sensitivity of 0.72
(95% CI¼ 0.67–0.76) and specificity of
0.63 (95% CI¼ 0.59–0.66), with a positive
predictive value of 51.1% (95% CI¼ 47%–
55%) and negative predictive value of
80.9% (95% CI¼ 77%–83%). Taken
together, these data suggest that the
ARCTIC score may be a valuable test for
exclusion rather than inclusion. However, it
should be noted that the ARCTIC score
was developed for use in trauma patients,
and that only 2% of our cohort were
trauma patients. Despite the low accuracy
of the ARCTIC score, the development and
validation of more accurate clinical scoring
systems may provide a means of identifying
patients at higher risk of developing ARC,
thus allowing targeted measurement of
CrCl; such methods warrant further
investigation to avoid reliance upon esti-
mated GFR.
The development of ARC significantly
impacts the PK of many drugs and poten-
tially leads to alterations in plasma concen-
trations of renally excreted drugs important
in ICU such as antibiotics, enoxaparin, and
anti-epileptics.2,7 This situation may not be
immediately obvious as few ICUs routinely
measure CrCl and estimated measures of
GFR have been shown to correlate poorly
with CrCl.2,12,18 Our ICU admits predomi-
nantly post-operative patients, patients with
sepsis, and patients with pancreatitis. A sig-
nificant proportion of these patients will
receive antibiotics either peri-operatively
or as part of treatment. In those patients
developing ARC, there is a risk that signif-
icant numbers of patients may not attain
therapeutic plasma antibiotic concentra-
tions without dose adjustment to match
their renal function. Subtherapeutic deliv-
ery of antibiotics is likely in turn to nega-
tively impact critical care outcomes.
Several recent guidelines, including the
Surviving Sepsis Guidelines, have recom-
mended dosing antibiotics based upon
PK/PD properties of antimicrobial
drugs.29 These guidelines highlight that
therapeutic underdosing is common in crit-
ically ill patients and that ARC may play a
role in this observation.29,30 The clinical
heterogeneity of sepsis and variability of
the population make it difficult to achieve
individualised antibiotic plasma concentra-
tions and may help explain why it has been
difficult to establish a relationship between
ARC and clinical outcome.
A significant number of patients in our
cohort were admitted postoperatively.
Although it was not possible to determine
how many patients were admitted elective-
ly, we anticipate that a proportion of these
patients were admitted following elective
surgery. Elective post-operative patients
are usually less unwell, have fewer organ
failures, and have better physiological and
haemodynamic parameters compared with
patients admitted non-electively to ICU.
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While it is unlikely that these patients were
admitted for longer than 24 hours post-
operatively, it is possible that inclusion of
these patients may have skewed our data
towards patients with a shorter length of
ICU stay, lower APACHE II score, youn-
ger age, and reduced renal dysfunction.
Despite this limitation, significantly more
of our patients were admitted non-
electively. Unfortunately, our hospital diag-
nosis coding does not allow us to determine
the reasons for admission beyond what is
presented. We acknowledge that a signifi-
cant proportion of patients included in
our study had a diagnosis of, ‘other.’ It is
therefore a limitation of our study that we
cannot further categorise these admission
diagnoses to elucidate the impact of diag-
nosis on ARC. Future studies should ensure
a high granularity of data collection and
diagnoses to ensure that the impact of indi-
vidual diagnosis on ARC is investigated.
An important population to consider is
those elective patients admitted post-
operatively, who represent an important
subgroup in which the effect of ARC on
the PK/PD of drugs may be particularly
relevant as these patients tend to be youn-
ger and healthier and will often have pro-
phylactic antibiotics administered
intraoperatively and perioperatively. Our
study is limited by not reporting antibiotic
concentrations with which to investigate the
impact of ARC; however, to our knowl-
edge, few ICUs titrate antibiotics according
to plasma concentrations and this is an area
of study consistently lacking in the litera-
ture. Specifically designed studies aimed at
defining the impact of ARC on patient out-
comes and measures to individualise patient
therapy based upon PK/PD measures are
urgently needed.
Conclusion
To the best of our knowledge, our study
represents the largest cohort of patients
with ARC admitted to intensive care in
the United Kingdom and one of the largest
cohorts of patients with ARC in the litera-
ture. We report an ARC prevalence of 47%
in our cohort. The prevalence of ARC was
greater among younger (vs. older) male
patients with lower (vs. higher) APACHE
II scores. Clinicians in ICUs need to be alert
to the possibility of ARC and the require-
ment for urinary CrCl measurement for its
diagnosis. This is particularly important in
patients at greater risk of ARC. Further
studies are required to fully understand
the effects of ARC on clinical outcomes.
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